Insider Buying: OPKO Health (NASDAQ:OPK) CEO Buys $759,800.00 in Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 580,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 19th. The stock was acquired at an average price of $1.31 per share, with a total value of $759,800.00. Following the completion of the purchase, the chief executive officer owned 216,126,448 shares in the company, valued at $283,125,646.88. This represents a 0.27% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, November 21st, Phillip Md Et Al Frost acquired 580,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.33 per share, for a total transaction of $771,400.00.
• On Tuesday, November 18th, Phillip Md Et Al Frost acquired 533,300 shares of OPKO Health stock. The stock was acquired at an average price of $1.27 per share, for a total transaction of $677,291.00.
• On Friday, October 31st, Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.42 per share, with a total value of $213,000.00.

OPKO Health Price Performance

OPK stock opened at $1.32 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.02 and a current ratio of 3.41. The firm has a 50 day moving average price of $1.44 and a 200-day moving average price of $1.37. OPKO Health, Inc. has a 52-week low of $1.11 and a 52-week high of $2.04. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -5.28 and a beta of 1.50.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.05. The company had revenue of $151.67 million during the quarter, compared to analyst estimates of $165.74 million. OPKO Health had a negative return on equity of 13.62% and a negative net margin of 28.10%.The firm’s revenue for the quarter was down 12.6% on a year-over-year basis. During the same quarter last year, the company earned $0.03 EPS. Equities research analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Cerity Partners LLC purchased a new stake in OPKO Health in the first quarter worth approximately $36,000. CWM LLC boosted its stake in shares of OPKO Health by 961.9% in the 1st quarter. CWM LLC now owns 74,503 shares of the biotechnology company’s stock worth $124,000 after buying an additional 67,487 shares during the last quarter. Private Advisor Group LLC grew its holdings in shares of OPKO Health by 56.7% in the first quarter. Private Advisor Group LLC now owns 55,301 shares of the biotechnology company’s stock worth $92,000 after acquiring an additional 20,000 shares during the period. Oak Thistle LLC bought a new stake in shares of OPKO Health in the first quarter worth $26,000. Finally, Inspire Advisors LLC purchased a new stake in OPKO Health during the first quarter valued at $78,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Jefferies Financial Group restated a “hold” rating and set a $1.60 price target (down from $2.00) on shares of OPKO Health in a report on Thursday, October 30th. Wall Street Zen upgraded shares of OPKO Health from a “strong sell” rating to a “hold” rating in a research note on Saturday, November 1st. JPMorgan Chase & Co. started coverage on shares of OPKO Health in a research note on Thursday. They issued a “neutral” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a report on Wednesday, October 8th. Finally, Zacks Research upgraded shares of OPKO Health from a “strong sell” rating to a “hold” rating in a report on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, OPKO Health presently has a consensus rating of “Hold” and a consensus price target of $2.28.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.